Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Clinical Pharmacokinetics|February 20, 2016
Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy VolunteersAkshanth R Polepally, Jennifer R King, Bifeng Ding, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 3, 2009
Sex-dependent disposition of acetaminophen sulfate and glucuronide in the in situ perfused mouse liverJin Kyung Lee, Koji Abe, Arlene S Bridges, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 16, 2011
Mechanisms underlying differences in systemic exposure of structurally similar active metabolites: comparison of two preclinical hepatic modelsGrace Zhixia Yan, Kim L R Brouwer, Gary M Pollack, et al.
Molecular Pharmacology|July 14, 2006
In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulationBjörn Bauer, Xiaodong Yang, Anika M S Hartz, et al.
Antimicrobial Agents and Chemotherapy|March 8, 2017
Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling TechniquesCharles S Venuto, Marianthi Markatou, Yvonne Woolwine-Cunningham, et al.
The Lancet. Gastroenterology & Hepatology|April 19, 2017
Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trialTania M Welzel, Tarik Asselah, Emily O Dumas, et al.
American Journal of Pharmaceutical Education|March 12, 2010
Roles of innovation in education deliveryRobert A Blouin, William H Riffee, Evan T Robinson, et al.
The International Journal on Drug Policy|February 9, 2019
Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapyJason Grebely, Gregory J Dore, Negar N Alami, et al.
Antimicrobial Agents and Chemotherapy|June 20, 2007
Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in miceXianbin Tian, Jun Li, Maciej J Zamek-Gliszczynski, et al.
The Journal of Infectious Diseases|December 12, 2017
Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin DosageAndrew H Talal, Emily O Dumas, Barbara Bauer, et al.
Pageof 7